October 12, 2020
Takeda Pharmaceutical said on October 8 that it has entered into a collaboration and licensing agreement with US-based Arrowhead Pharmaceuticals for the development of the US company’s investigational drug candidate ARO-AAT for the treatment of alpha-1 antitrypsin-associated liver disease (AATLD)...read more